Article
On target: Rational approaches to KRAS inhibition for treatment of non-small cell lung carcinoma.
Lung cancer (Amsterdam, Netherlands) - 1 Oct 2021
Lindsay Colin R, Garassino Marina C, Nadal Ernest, Öhrling Katarina, Scheffler Matthias, Mazières Julien
Abstract excerpt
Non-small cell lung carcinoma (NSCLC) is a leading cause of cancer death. Approximately one-third of patients with NSCLC have a KRAS mutation. KRASG12C, the most common mutation, is found in ~13% of patients. While KRAS was long considered 'undruggable', several novel direct KRASG12C inhibitors have shown encouraging signs of efficacy in phase I/II trials and one of these (sotorasib) has recently been approved by...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.